A placebo-controlled study of 100 outpatients with mixed heroin-amphetamine addiction showed that implanted naltrexone, designed to block opiate effects for 8–10 weeks, led to 52% of patients remaining in treatment and 38% having urine samples free of both drugs at 10 weeks, compared to 28% remaining and 16% drug free for the placebo implant. Tiihonen et al. (p. 531) report that use of other substances, such as alcohol, did not increase. The number needed to treat, i.e., number of patients who have to be treated for one to benefit, was three. In an editorial, Penetar (p. 455) points out that a puzzling aspect of the study is that craving decreased in both treated and placebo groups, even though remission rates differed. Naltrexone did decrease euphoria in patients who continued to use amphetamine.